Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

Fundamental&Clinical Pharmacology,Volume 32, Issue 5, Page 547-547, October 2018.

Source: Fundamental and Clinical Pharmacology - September 13, 2018 Category: Drugs & Pharmacology Authors: Matthias D. Hofer Source Type: research